Seriously all, this is a direct quote of Tharlows CXS post:
-------------------
"I can't believe this is trading under $2. Drug has huge potential, and this could easily be over $3 within 12 months. And adding a big-hitting partner to the mix makes this a simple pick for a home run.
A hidden gem."
-------------------
Go check out the current clinical trials for Ceflatonin (ChemGenexs lead): It's in a phase-II/III for a subset of Chronic Myeloid Leukaemia patients that represent less than 5% of all cases. Considering there are only 4,000 odd new cases per year in the USA, that comes out to a target market of 200 patients per year...WOW! On the other hand, liver cancer has an incidence of about 20,000 cases per year in the USA of which 15-20% are eligible for surgery - a target market of 3,000 to 4,000 cases per year (that's 20x the potential of ChemGenex's drug) plus many more in Asia.....plus there's trialing of PI-88 in lung, prostate, they are potentially huge markets.
Go figure. Tharlow makes NO SENSE and is INCONSISTENT in his analysis.
Nong.
- Forums
- ASX - By Stock
- PGL
- price target 3.50
price target 3.50, page-5
Featured News
Add PGL (ASX) to my watchlist
(20min delay)
|
|||||
Last
43.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $71.64M |
Open | High | Low | Value | Volume |
43.5¢ | 43.5¢ | 43.5¢ | $69.31K | 159.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 788030 | 43.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
44.0¢ | 95406 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 788030 | 0.435 |
2 | 100000 | 0.430 |
1 | 55597 | 0.425 |
1 | 83416 | 0.420 |
1 | 16000 | 0.415 |
Price($) | Vol. | No. |
---|---|---|
0.440 | 95406 | 2 |
0.445 | 97049 | 5 |
0.450 | 128910 | 7 |
0.490 | 21811 | 2 |
0.510 | 20000 | 1 |
Last trade - 15.48pm 28/06/2024 (20 minute delay) ? |
Featured News
PGL (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online